You are here


 - Patient

Since open enrollment for the health insurance exchanges began in October 2013, millions of more Americans have received coverage and their access to care and self-reported health have improved, according to an analysis of telephone surveys conducted in the past two years.

 - cholesterol

The FDA’s approval of the first proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor brought about excitement for some with regards to the effectivenss of the new class of drugs in lowering cholesterol. It also raised concerns about the high costs associated with the medications.

 - cholesterol

The FDA has approved alirocumab, an injectable cholesterol-lowering medication and the first commercially available proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor. Alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) is approved as an adjunct to diet and statins to treat patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease who have not been able to lower their low-density lipoprotein (LDL) cholesterol.

 - HeartDNA

New research is revealing the level at which radiation exposure received during CT scanning damages DNA.

 - aspirin

More than 70 percent of adults with atherosclerotic cardiovascular disease (ASCVD) in 2013 took aspirin daily or every other day to reduce the risk for myocardial infarction, ischemic stroke and fatal coronary events, according to a Centers for Disease Control and Prevention (CDC) report.